

Somatuline[®] Depot (lanreotide) – First-time generic

- On May 23, 2024, Cipla launched an [AB-rated](#) generic version of Ipsen's [Somatuline Depot \(lanreotide\)](#) 120 mg/0.5 mL injection.
 - Cipla also received FDA approval of generic Somatuline Depot 60 mg/0.2 mL and 90 mg/0.3 mL injections. Launch of these strengths is pending.
- Somatuline Depot is approved for the following indications:
 - Long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option
 - Treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival
 - Treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.